RxDoctor Payments DataLook up a doctor →

Daniel Green, MD

Interventional Cardiology · Greenville, SCNPI 1790929230

Payments from drug & device makers

$256,209in general payments, 2019–2025

Across 565 payments — averaging $453.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$159K
  • Janssen Research & Development, LLC$85K
  • Edwards Lifesciences$2K
  • Boston Scientific$2K
  • Abiomed$2K
  • Medtronic$688
  • plus $6K from 34 others

What the payments were for

  • Travel & lodging$3,03324%
  • Food & beverage$9,68276%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$256,209 in reported general payments places this provider in the 90th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina

Medicare billing

Part B allowed, 2024
$314,051
Medicare patients
1,958
Services billed
4,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban417$426,943
XareltoRivaroxaban128$126,609
Repatha SureclickEvolocumab166$121,149
EntrestoSacubitril/Valsartan61$73,127
JardianceEmpagliflozin36$38,809
MultaqDronedarone Hcl31$36,871
Praluent PenAlirocumab31$16,008
Ranolazine ErRanolazine75$6,438
Metoprolol Succinate392$4,933
Atorvastatin Calcium338$3,516
Carvedilol422$3,319
Rosuvastatin Calcium141$2,687
Flecainide Acetate41$2,243
Losartan Potassium236$2,201
Nitroglycerin133$1,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$374$426,943417 claims
Johnson & JohnsonXarelto$649$126,609128 claims
NovartisEntresto$672$73,12761 claims
Boehringer IngelheimJardiance$171$38,80936 claims
Sanofi-aventis U.S. LLCMultaq$141$36,87131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →